Nivolumab and ipilimumab improve PFS in newly diagnosed metastatic colorectal cancer
The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) improved progression-free survival (PFS) by blinded independent central review (BICR) compared to the chemotherapy chosen by investigators as front-line treatment for microsatellite patients. resulted in statistically significant and clinically meaningful improvements in Meets one of the two primary endpoints of the Phase 3 CheckMate-8HW study in unstable-high […]